Under the agreement, BioNTech will have access to certain Sanofi manufacturing sites and expertise. Initial supplies of the vaccine will be produced at Sanofi’s manufacturing site in Frankfurt, Germany.
“We have made the decision to support BioNTech and Pfizer in manufacturing their COVID-19 vaccine in order to help address global needs, given that we have the technology and facilities to do so,” Sanofi CEO Paul Hudson said in a news release.
Sanofi is also developing a COVID-19 vaccine candidate with GlaxoSmithKline. The drugmakers plan to launch a new phase 2 trial for their vaccine in February.
More articles on pharmacy:
Walgreens taps Starbucks exec as new CEO
COVID-19 vaccine should be available to all who want it by spring, Biden says
Regeneron says its COVID-19 antibody drug prevented COVID-19 in clinical trial
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
